A study of toripalimab plus chemotherapy before head and neck cancer surgery
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding an immunotherapy drug (toripalimab) to chemotherapy before surgery can help shrink tumors and improve outcomes for patients with locally advanced head and neck cancer. It aims to see if this combination is better than surgery alone or surgery with chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with head or neck cancer that has not spread to other parts of the body.
- The cancer must be in the mouth, throat, tonsils, voice box, or lower throat.
- Doctors must think the cancer can be surgically removed.
- You must have a protein called PD-L1 on your tumor cells (a lab test will check this).
- You must be 18 to 70 years old and have a good level of daily activity.
- You must not have had major surgery or radiation for this cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.